6 major contraindications for taking entrectinib/Luo Shengquan

Entrectinib (Entrectinib), as a targeted therapy drug, has shown significant efficacy in patients with specific gene-driven solid tumors and non-small cell lung cancer. However, there are clear contraindications during its use, and medical instructions need to be strictly followed. First of all, patients who are known to be allergic to entrectinib or its excipients are prohibited from using this drug to avoid severe allergic reactions or drug-induced shock. A history of allergies includes reactions such as rash, difficulty breathing, or a sudden drop in blood pressure.

Secondly, pregnant and lactating women should use it with caution. Animal studies have shown that entrectinib may cause potential toxicity to the fetus. Female patients should take effective contraceptive measures during treatment and after stopping the drug. Lactating patients should avoid breastfeeding to prevent the drug from affecting the baby through milk.

Third, it is contraindicated in patients with severe hepatic impairment before risk assessment. Entrectinib may cause an increase in liver enzymes during liver metabolism, and its use in patients with severe liver dysfunction may aggravate toxicity and increase treatment risks. Fourth, patients with severe cardiovascular disease or uncontrolled arrhythmia should also avoid using it to avoid increasing the probability of cardiac events.

Fifth, patients who are currently taking entrectinib and have significant drug interactions should use it with caution. For example, strong CYP3A inhibitors or inducers may significantly change plasma concentrations, thereby increasing toxicity or reducing efficacy. When these drugs cannot be replaced or discontinued, dosage adjustments or monitoring should be made under the guidance of a professional physician. Sixth, it should be used with caution in children, adolescents, or patients in age groups that have not been fully verified in clinical trials. The current clinical data are mainly for adult patients, and there may be safety and dosage risks when used in children and adolescents.

In summary, observing the above six contraindications can minimize the potential risks of entrectinib. Patients should truthfully provide medical history and medication information before treatment, and should be followed up and monitored regularly during treatment to ensure safe medication and obtain the best efficacy.

Reference materials:https://www.roche.com/products/rozlytrek